INNATE PHARMA : Annual General Meeting of shareholders and the release of its reference document (in french)
27 Avril 2016 - 11:34AM
Innate Pharma to hold its Annual General
Meeting of shareholders on June 2, 2016 and the release of its
reference document (in french)
Innate Pharma (the "Company" - Euronext Paris:
FR0010331421 - IPH) will hold its Annual General Meeting of
Shareholders ("AGM") on June 2, 2016, at 10:00 am in its
headquarters, 117 avenue de Luminy, F-13009 Marseille.
The Notice of Meeting of this Shareholders'
Meeting was published this day, in the French official legal
bulletin ("BALO"). It includes the agenda, the proposed resolutions
as well as instructions to participate and vote in this Meeting. It
is also available on the Company's website, in the investors' room
(http://innate-pharma.com/en/AGMdocuments).
All documentation regarding this AGM will be
made available to shareholders in accordance with existing
regulations and will be available on the Company's website on May
12, 2016.
The 2015 Reference Document (in French) and
Financial Report (included in the Reference Document) was released
on April 25, 2016 under number D.16-0397, and is available on the
website of the Company (http://innate-pharma.com) as well as on the
website of the AMF, the French stock-market authorities
(www.amf-france.org). Hard copies are available upon request to the
investor relations department of the Company.
An English translation of the 2015 Reference
Document will be made available on Innate Pharma's website during
the month of May 2016.
Precision regarding the AGM:
Only shareholders having registered their shares
at least two business days prior to the date of the AGM, by
midnight Paris time, will be able to attend.
Shareholders holding "au porteur" (bearer)
shares will need to obtain an "attestation de participation"
(certificate of shareholding) from their brokers. This "attestation
de participation" must be attached to the proxy form or to the
appropriate voting form if shareholders wish to designate a proxy
or vote by post. The "attestation de participation" may replace the
admission card for shareholders wishing to attend the AGM in
person.
Written questions from shareholders must be
received from the day of the publication of the official
convocation to the AGM up until four business days prior to the AGM
(by registered letter, addressed to the registered office, or by
e-mail to investors@innate-pharma.com).
Shareholders may obtain the legal documentation
in preparation of the AGM (as described in article R. 225-83 of the
French "Code de Commerce") by sending a request:
- by regular mail to Innate Pharma, Shareholders Services, 117
avenue de Luminy, BP 30191, F-13009 Marseilles, France or
- by e-mail to investors@innate-pharma.com.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
Innate Pharma specializes in immuno-oncology, a
new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells.
The Company has pioneered the development of
antibodies that block inhibitory checkpoint receptors on NK cells.
Today, Innate Pharma has three first-in-class antibodies in
clinical development in immuno-oncology and a pipeline of
preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into
alliances with leaders in the biopharmaceutical industry such as
Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk
A/S.
Based in Marseille, France, Innate Pharma had
118 employees as at December 31, 2015. The company is listed on
Euronext-Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical Information about Innate Pharma
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website (http://www.amf-france.org) or on Innate Pharma's
website (www.innate-pharma.com).
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director,
Investor Relations |
Marie
Puvieux Mob.: +33 (0)6 10 54 36 72 |
Tel.: +33 (0)4 30 30 30 87 |
|
investors@innate-pharma.com |
presse@atcg-partners.com |
PR in English http://hugin.info/155662/R/2006958/741676.pdf
HUG#2006958
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024